MYC

MYC is a proto-oncogene that encodes a nuclear transcription factor (c-MYC) involved in regulation of cell growth, proliferation, metabolism, protein synthesis, and apoptosis.

Oncology relevance (for pharmacists):

• Dysregulation or overexpression of MYC (via gene amplification, translocation, or increased transcription) leads to uncontrolled cellular proliferation.
• Classic example: Burkitt lymphoma, characterized by MYC translocation—most commonly t(8;14) involving the immunoglobulin heavy-chain locus.
• Also implicated in diffuse large B-cell lymphoma (DLBCL), breast cancer, lung cancer, and many solid tumors.

Clinical significance:

• Prognostic marker: MYC overexpression often correlates with aggressive disease and poor prognosis.
• Therapeutic implications:
  • MYC is considered “undruggable” directly, but therapies may target MYC-driven pathways (e.g., BET inhibitors, CDK inhibitors—investigational).
  • In lymphomas, “double-hit” or “triple-hit” tumors (MYC with BCL2 and/or BCL6 rearrangements) require intensified treatment regimens.

Key takeaway for oncology pharmacists:

MYC status influences risk stratification, treatment intensity, and clinical trial eligibility, even though direct MYC inhibitors are not standard of care.